Published in Cancers (Basel) on August 26, 2016
lncRNA co-expression network model for the prognostic analysis of acute myeloid leukemia. Int J Mol Med (2017) 0.75
Aberrant Signaling Pathways in T-Cell Acute Lymphoblastic Leukemia. Int J Mol Sci (2017) 0.75
Wnt/beta-catenin signaling in development and disease. Cell (2006) 30.09
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 22.86
Wnt signalling in stem cells and cancer. Nature (2005) 19.26
Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 18.84
Hematopoiesis: an evolving paradigm for stem cell biology. Cell (2008) 11.95
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med (2004) 11.29
The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood (2004) 6.92
NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A (2006) 6.80
c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev (2006) 6.19
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med (2001) 4.83
Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol (2007) 4.75
The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science (2010) 4.37
Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell (2007) 4.21
Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. Cell Stem Cell (2008) 3.62
WNT signalling in the immune system: WNT is spreading its wings. Nat Rev Immunol (2008) 3.46
Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. Immunity (2000) 3.19
Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell (2011) 2.89
Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell (2012) 2.89
Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc Natl Acad Sci U S A (2009) 2.76
Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2004) 2.60
Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue. Cancer Cell (2003) 2.49
Signaling pathways governing stem-cell fate. Blood (2007) 2.38
The canonical Wnt signaling pathway plays an important role in lymphopoiesis and hematopoiesis. Eur J Immunol (2008) 2.37
Canonical wnt signaling regulates hematopoiesis in a dosage-dependent fashion. Cell Stem Cell (2011) 2.18
The TCF-1 and LEF-1 transcription factors have cooperative and opposing roles in T cell development and malignancy. Immunity (2012) 2.15
A critical role for TCF-1 in T-lineage specification and differentiation. Nature (2011) 2.15
Wnt-related molecules and signaling pathway equilibrium in hematopoiesis. Cell Stem Cell (2009) 2.00
Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol (2004) 1.96
Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukaemia. Oncogene (2005) 1.70
Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling. Blood (2013) 1.70
β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell (2010) 1.65
Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell (2010) 1.64
Canonical and non-canonical Notch ligands. Curr Top Dev Biol (2010) 1.62
Separation of Notch1 promoted lineage commitment and expansion/transformation in developing T cells. J Exp Med (2001) 1.62
Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia (2006) 1.58
LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia. Nat Med (2006) 1.52
Retracted Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. Blood (2006) 1.49
Oncogenic homeodomain transcription factor E2A-Pbx1 activates a novel WNT gene in pre-B acute lymphoblastoid leukemia. Proc Natl Acad Sci U S A (1999) 1.48
Beta-catenin stabilization stalls the transition from double-positive to single-positive stage and predisposes thymocytes to malignant transformation. Blood (2007) 1.48
Wnt signaling strength regulates normal hematopoiesis and its deregulation is involved in leukemia development. Leukemia (2011) 1.37
Small molecule inhibitors of Wnt/beta-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Neoplasia (2010) 1.35
Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma. Leukemia (2007) 1.34
Differential niche and Wnt requirements during acute myeloid leukemia progression. Blood (2011) 1.32
Chronic myelogenous leukemia molecular signature. Oncogene (2003) 1.31
Hematopoietic stem cells: concepts, definitions, and the new reality. Blood (2015) 1.30
Wnt signaling pathway is epigenetically regulated by methylation of Wnt antagonists in acute myeloid leukemia. Leukemia (2009) 1.29
Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis. Leukemia (2014) 1.28
High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia. Blood (2012) 1.21
WNT5A, a putative tumour suppressor of lymphoid malignancies, is inactivated by aberrant methylation in acute lymphoblastic leukaemia. Eur J Cancer (2007) 1.20
Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1;19) translocation induces apoptosis. Oncogene (2005) 1.20
Notch1 co-opts lymphoid enhancer factor 1 for survival of murine T-cell lymphomas. Blood (2007) 1.18
Loss of expression of the WNT/beta-catenin-signaling pathway transcription factors lymphoid enhancer factor-1 (LEF-1) and T cell factor-1 (TCF-1) in a subset of peripheral T cell lymphomas. Am J Pathol (2003) 1.18
Frizzled 9 knock-out mice have abnormal B-cell development. Blood (2004) 1.16
Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction. Blood (2005) 1.16
Small molecule inhibitors of WNT signaling effectively induce apoptosis in acute myeloid leukemia cells. Eur J Haematol (2008) 1.14
Wnt signaling in normal and malignant hematopoiesis. Cold Spring Harb Perspect Biol (2013) 1.14
Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation. Leuk Lymphoma (2010) 1.13
Gamma-catenin contributes to leukemogenesis induced by AML-associated translocation products by increasing the self-renewal of very primitive progenitor cells. Blood (2004) 1.13
Notch and Wnt signaling in T-lymphocyte development and acute lymphoblastic leukemia. Leukemia (2006) 1.07
The nuclear effector of Wnt-signaling, Tcf1, functions as a T-cell-specific tumor suppressor for development of lymphomas. PLoS Biol (2012) 1.06
Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients. Leukemia (2009) 1.06
Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood (2014) 1.05
WNT5A is epigenetically silenced in hematologic malignancies and inhibits leukemia cell growth as a tumor suppressor. Blood (2007) 1.04
The thymus and T-cell commitment: the right niche for Notch? Nat Rev Immunol (2006) 1.02
Epigenetic regulation of the non-canonical Wnt pathway in acute myeloid leukemia. Cancer Sci (2009) 1.01
Genome-wide analysis of gene-expression profiles in chronic myeloid leukemia cells using a cDNA microarray. Int J Oncol (2003) 0.99
CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression. J Clin Invest (2012) 0.99
Mutations of the Notch1 gene in T-cell acute lymphoblastic leukemia: analysis in adults and children. Leukemia (2005) 0.98
BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res (2000) 0.95
Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol (2008) 0.94
Wnt3A activates canonical Wnt signalling in acute lymphoblastic leukaemia (ALL) cells and inhibits the proliferation of B-ALL cell lines. Br J Haematol (2006) 0.93
Preferential hypermethylation of the Dickkopf-1 promoter in core-binding factor leukaemia. Br J Haematol (2007) 0.92
Laforin negatively regulates cell cycle progression through glycogen synthase kinase 3beta-dependent mechanisms. Mol Cell Biol (2008) 0.92
Clinical significance of lymphoid enhancer-binding factor 1 expression in acute myeloid leukemia. Leuk Lymphoma (2013) 0.89
Deciphering the role of Notch signaling in lymphopoiesis. Curr Opin Immunol (2002) 0.89
Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts. Cancer Res (2001) 0.89
Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia (2014) 0.88
beta-catenin is involved in N-cadherin-dependent adhesion, but not in canonical Wnt signaling in E2A-PBX1-positive B acute lymphoblastic leukemia cells. Exp Hematol (2008) 0.87
β-Catenin and AKT are promising targets for combination therapy in acute myeloid leukemia. Leuk Res (2013) 0.87
Leukemia stem cells in T-ALL require active Hif1α and Wnt signaling. Blood (2015) 0.86
Stem cell self-renewal: lessons from bone marrow, gut and iPS toward clinical applications. Leukemia (2011) 0.85
γ-Catenin is overexpressed in acute myeloid leukemia and promotes the stabilization and nuclear localization of β-catenin. Leukemia (2012) 0.85
Cross talk between Wnt/β-catenin and Irf8 in leukemia progression and drug resistance. J Exp Med (2013) 0.85
Deregulated WNT signaling in childhood T-cell acute lymphoblastic leukemia. Blood Cancer J (2014) 0.85
Methylation status of Wnt signaling pathway genes affects the clinical outcome of Philadelphia-positive acute lymphoblastic leukemia. Cancer Sci (2008) 0.84
Infrequent Wnt inhibitory factor-1 (Wif-1) methylation in chronic lymphocytic leukemia. Leuk Res (2006) 0.84
Regeneration-associated WNT signaling is activated in long-term reconstituting AC133bright acute myeloid leukemia cells. Neoplasia (2012) 0.83
Signal transduction pathways regulating hematopoietic stem cell biology: introduction to a series of Spotlight Reviews. Leukemia (2012) 0.80
Survival regulation of leukemia stem cells. Cell Mol Life Sci (2015) 0.79
Oestrogen receptor (ER) analysis in B-cell chronic lymphocytic leukemia: correlation of biochemical and immunocytochemical methods. Leuk Res (1990) 0.79
Tales of the unexpected: Tcf1 functions as a tumor suppressor for leukemias. Immunity (2012) 0.78
Disruption of pre-B-cell receptor signaling jams the WNT/β-catenin pathway and induces cell death in B-cell acute lymphoblastic leukemia cell lines. Leuk Res (2015) 0.78
Evolutionarily conserved signaling pathways: acting in the shadows of acute myelogenous leukemia's genetic diversity. Clin Cancer Res (2015) 0.78
Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia. Clin Cancer Res (2015) 0.78
Caught in a Wnt storm: Complexities of Wnt signaling in hematopoiesis. Exp Hematol (2016) 0.77
Hematopoietic and Leukemic Stem Cells Have Distinct Dependence on Tcf1 and Lef1 Transcription Factors. J Biol Chem (2016) 0.77
An integrated approach of gene expression and DNA-methylation profiles of WNT signaling genes uncovers novel prognostic markers in acute myeloid leukemia. BMC Bioinformatics (2015) 0.76
SKLB-677, an FLT3 and Wnt/β-catenin signaling inhibitor, displays potent activity in models of FLT3-driven AML. Sci Rep (2015) 0.76
Genetic abnormalities associated with acute lymphoblastic leukemia. Cancer Sci (2016) 0.76